299964-12-8

Upstream product

• 86-90-8 4-bromophthalic anhydride 
• 56-12-2 4-amino-n-butyric acid 
• 6941-75-9 5-Bromoisoindoline-1,3-dione 

Downstream Products

• 1099323-67-7 4-(5-bromo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butyryl N-(phenyl)amide 
• 1099357-66-0 C₂₀H₁₉BrN₂O₃ 
• 1099804-23-5 C₁₈H₁₄BrFN₂O₃ 
• 1272318-28-1 C₂₀H₁₇BrN₄O₅ 
• 1272318-29-2 C₂₀H₁₈BrN₃O₄ 
• 1272318-30-5 C₁₉H₁₆BrN₃O₄ 
• 1272318-33-8 C₂₁H₁₈BrN₃O₃ 
• 1272318-32-7 C₂₀H₁₈BrN₃O₅ 
• 1272318-24-7 C₂₂H₂₂BrN₃O₅ 
• 1272318-25-8 C₁₉H₁₆BrN₃O₄ 
• 1272318-26-9 C₁₉H₁₅BrClN₃O₃ 
• 1272318-27-0 C₂₀H₁₉BrN₄O₃ 

Relevant academic research and scientific papers

Discovery and structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway

Aberrant Wnt signaling has been implicated in a variety of disease. Inhibition of the Wnt pathway is an attractive approach for developing new therapeutics for the treatment of various types of fibrosis and cancers. We have discovered the phthalimide-phenylpyridine conjugate as a novel hit compound for the Wnt pathway inhibitors from cellular screening. The structure-activity relationship of these compounds suggested both of the substituent group on the phthalimide fragment and the structure of the linker were critical to the inhibitory activity. The most potent compound was about 10-folds more potent than the hit compound, with IC50 value of 0.28 ± 0.01 μM.

Amide compounds for regulating WNT signal channel and application of compounds

The invention belongs to the technical field of medicine, and particularly relates to amide compounds for regulating a WNT signal channel and an application of the compounds. The compounds have a structure represented by a general formula I shown in the description.

Anticonvulsant and neurotoxicity evaluation of new bromophthalimido-butyryl hydrazones

A new series of N-aryl/alkylidene-4-(5-bromo-1,3-dioxo-1,3-dihydro-2H- isoindol-2-yl) butanoyl hydrazones (4a-I) were synthesized and evaluated for their anticonvulsant activity in MES test according to the protocols of Antiepileptic Drug Development (ADD

Anticonvulsant and neurotoxicity evaluation of new bromophthalimidobutyryl amide derivatives

A series of 4-(5-bromo-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-butyryl N-(substituted phenyl) amides (3a-l) were synthesized and evaluated for their anticonvulsant activity in MES test according to the protocols of Antiepileptic Drug Development (ADD) programme of National Institutes of Health (NIH, Bethesda, USA).The most active compounds of the series were 3a, 3c, 3d, 3f, 3g, 3i and 3k at the dose of 30 mg/kg (i.p.) 0.5 h and 4 h after administration. In neurotoxic screen (NT), 3d, 3i and 3k were less toxic when compared with the other compounds.